Avandia :: GlaxoSmithKline presents Avandia data to FDA
Health is a unity and harmony within the mind, body and spirit which is unique to each person, and is as defined by that person. The level of wellness or health is, in part, determined by the ability to deal with and defend against stress. Health is determined by physiological, psychological, socio-cultural, spiritual, and developmental stage variables.
logo - spiritindia - Avandia :: GlaxoSmithKline presents Avandia data to FDA

GlaxoSmithKline presents Avandia data to FDA

Avandia :: GlaxoSmithKline presents Avandia data to FDA

Avandia :: GlaxoSmithKline presents Avandia data to FDA

The following summarizes GlaxoSmithKline?s [NYSE: GSK] presentation of data on Avandia? (rosiglitazone maleate) to an Advisory Committee of the Food and Drug Administration (FDA) on July 30, 2007.

The GSK presentation demonstrates the weight of scientific evidence available to address a question of increased risk of cardiovascular ischemic events.

This question was raised by different meta-analyses performed by GSK, the FDA and one published in the NEJM.

Although a meta-analysis can help raise scientific questions for further investigation, such analyses can also have significant limitations. GSK believes a full and scientific evaluation of all the data does not confirm the safety questions originally raised.

Long-term clinical trials ? particularly those designed to test a specific outcome in patients with the disease ? are the most robust tools available to answer questions raised by meta-analyses. A 1997 published review of meta-analyses revealed 33% of the conclusions of meta-analyses are not confirmed by subsequent clinical trials.

Avandia is the most widely studied oral anti-diabetic medicine for the treatment of type 2 diabetes. The extensive data for Avandia includes:

116 clinical trials in over 52,000 patients. These include:

Three, long-term clinical trials in more than 14,000 patients: ADOPT, DREAM, RECORD, with RECORD specifically studying cardiovascular effects

A study in a high cardiovascular-risk population: PPAR

Three epidemiological studies reflecting real life use of diabetes medicines in more than 1.3 million diabetic patients.

Additionally, four other ongoing long-term studies will increase available data on the cardiovascular safety of Avandia: BARI-2D, ACCORD, VADT, APPROACH.

Across the extensive dataset for Avandia, there is no consistent or systematic evidence that Avandia increases the risk of heart attack or cardiovascular death in comparison to other anti-diabetic medicines.




(Avandia :: GlaxoSmithKline presents Avandia data to FDA published at SpiritIndia on Monday, July 30, 2007)



Avandia

Search more information on Avandia, Avandia books

Recently posted related articles on Avandia :

  1. Diabetes :: European Medicine Agency confirms positive Avandia benefit risk assessment
  2. Diabetes :: JAMA articles do not confirm difference in safety of Avandia and Actos, says GSK
  3. Avandia :: Glaxo updates prescribing information for Avandia in US
  4. Avandia :: Reanalysis of controversial meta-analysis says writing off rosiglitazone may be premature
  5. Avandia :: Keep GSK diabetes drug Avandia available to US patients
  6. Avandia :: FDA Advisory Panel supports Glaxo's diabetes drug Avandia
  7. Avandia :: GlaxoSmithKline presents Avandia data to FDA
  8. Diabetes :: New review adds more reasons to avoid diabetes drug Avandia
  9. Avandia :: Newly published data from large study support cardiovascular safety of Avandia
  10. Avandia :: RECORD analysis shows cardiovascular safety of Avandia

Most related articles:

- Avandia :: GlaxoSmithKline presents Avandia data to FDA
- Avandia :: FDA Advisory Panel supports Glaxo's diabetes drug Avandia - 19.4
- Avandia :: Keep GSK diabetes drug Avandia available to US patients - 18.3
- Avandia :: Glaxo updates prescribing information for Avandia in US - 16.8
- Diabetes :: FDA has requested black box warnings for two diabetes medications - 16.5
- Avandia :: Data affirms Avandia cardiovascular safety profile - 16
- Diabetes :: GlaxoSmithKline strongly defends its record on Avandia - 15.6
- Avandia :: Newly published data from large study support cardiovascular safety of Avandia - 15.2
- Avandia :: RECORD analysis shows cardiovascular safety of Avandia - 14.7
- Diabetes :: FDA Issues Safety Alert on GSK's Avandia to treat type 2 diabetes - 13.4


»»   Child Care :: Test scores slow under No Child Left Behind reforms, gauged by states/federal assessment
««   Cervical Cancer :: HPV vaccine & pap test essential to cure cervical cancer






Tools
Daily calorie need
Homeo tips
Homeo softwares
Associations
NHMC Alumni
IFH
PHS
Vital Informer
Articles & news
Education
Homeo articles
Homeopathy cases
Homeopathic Remedies
You
Authors
Submit article
Your account
Testimonials
About
About us
Advertisers
Advertising
Linking us
Disclaimer
Privacy policy

The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com